Coya Therapeutics (COYA) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on therapies that enhance regulatory T cell (Treg) function to treat neurodegenerative, autoimmune, and metabolic diseases.

• Lead asset COYA 302 is a Treg-enhancing biologic combining low-dose interleukin-2 and CTLA4-Ig, targeting neurodegenerative disorders.

• Pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, with recent expansion into inflammatory diseases with COYA 303.

• Operations are primarily dedicated to R&D, clinical development, and expanding intellectual property.

Financial performance and metrics

• Net losses were $13.4 million for the six months ended June 30, 2025, compared to $7.9 million for the same period in 2024.

• Accumulated deficit as of June 30, 2025, was $54.1 million.

• Primary cash use is for operating expenses, mainly R&D and general and administrative costs.

• Ongoing need for substantial additional capital to support operations and growth strategy.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including funding administrative expenses, R&D, manufacturing, clinical trials, regulatory advancement, acquisitions, investments, working capital, debt reduction, and capital expenditures.

• Management retains broad discretion over allocation of proceeds.